Asenapine: A review of the data

Psychopharm Review

Volumn 44, Issue 12, 2009, Pages 89-94

  Janicak, Philip G ^a   Rado, Jeffrey T ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ASENAPINE; FLUVOXAMINE; HALOPERIDOL; ILOPERIDONE; LITHIUM; OLANZAPINE; PAROXETINE; RISPERIDONE; VALPROIC ACID;

BIPOLAR I DISORDER; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERPROLACTINEMIA; HYPESTHESIA; LIPID BLOOD LEVEL; LIVER METABOLISM; MANIA; NONHUMAN; ORAL HYPOESTHESIA; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 78649386171     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.idt.0000363156.07272.2e     Document Type: Review

References (21)

1. ShahidM,Walker GB, Zorn SH, et al.Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.J Psychopharmacol 2009;23(1):65-73.
2. Franberg O, Marcus MM, Jardemark K, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 2008;196:417-429.
3. Marston HM,Young JW,Martin FD, et al.Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology 2009;May 22.Available at: www.springerlink.com/content/q7nv508128276187/ fulltext.pdf.
4. Henry B, Grimwood S, de Greef H, et al. Asenapine: a translational analysis of receptor occupancy in human and rat brain with therapeutic implications. Presented at the Art and Science of Personalizing Treatments for Mental Disorders 48th annual meeting, National Institute of Mental Health New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008:I-67.
5. Tarazi F, Moran-Gates T,Wong E, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2008 Nov 21 [Epub ahead of print]. Available at: http://jop.sagepub. com/cgi/rapidpdf/ 0269881108095704v2.pdf.
6. Tarazi FI, ChoiYK, GardnerM, et al.Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63(5):413-420.
7. Tarazi FI, Moran-Gates,Wong EHF, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology 2008;198(1):103-111.
8. Franberg O, Marcus MM, Ivanov V, et al. Asenapine elevates cortical dopamine, noradrenaline, and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology 2009;204(2):251-264.
9. Peeters PAM, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics: influence of hepatic and renal impairment. Presented at the American Psychiatric Association 161st annual meeting, Washington, DC, May 3-8, 2008.
10. Potkin SG, Fleming K, Binneman B, et al. Asenapine cognitive function effects in acute schizophrenia: a placebo- and risperidone-controlled trial. Presented at the International Congress on Schizophrenia Research, Colorado Springs, CO, March 28-April 1, 2007.
11. Cazorla P, Panagides J, Alphs L, et al. Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia. Presented at the American Psychiatric Association 161st annual meeting, Washington, DC, May 3-8, 2008.
12. Kane JM, Zhao J, Cohen M, et al. Efficacy and safety of asenapine in patients with acute schizophrenia. Presented at the Art and Science of Personalizing Treatments for Mental Disorders 48th annual meeting, National Institute of Mental Health New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008;II-62.
13. Kane J, Zhao J, Cohen M, et al. Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia. Schizophr Res 2008;98:3-199.
14. McIntyre R, Panagides J, Alphs L, et al. Treatment of mania in bipolar I disorder: A placebo- and olanzapine- controlled trial of asenapine (ARES 7501005). Paper presented at the 20th European College of Neuropsychopharmacology Congress, Vienna, October 13-17, 2007.
15. McIntyre R, Panagides J, Alphs L, et al. Efficacy and tolerability of asenapine and olanzapine in acute mania: a double-blind extension study (ARES 7501006). Presented at the 20th European College of Neuropsychopharmacology Congress, Vienna, October 13-17, 2007.
16. McIntyre R, Hirschfeld R, Alphs L, et al. Randomized and placebo-controlled studies of asenapine in the treatment of acute mania in bipolar I disorder. Presented at the Art and Science of Personalizing Treatments for Mental Disorders 48th annual meeting, National Institute of Mental Health New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008;II-16.
17. McIntyre R, Hirschfeld R, Alphs L, et al. Asenapine in the treatment of acute mania in bipolar I disorder: outcomes from two randomized and placebo-controlled trials. J Affect Disord 2008;107:S53-S122.
18. McIntyre RS, Panagides J,Alphs L, et al.Asenapine versus olanzapine in acute mania: a double-blind extension study (Ares 7501006). Presented at the Society of Biological Psychiatry 62nd annual Scientific Convention and Meeting, San Diego, May 17-18, 2007.
19. McIntyre RS. Asenapine in bipolar disorder. P T 2008;33(6):364-367.
20. Weber J, McCormack PL. Asenapine. CNS Drugs 2009;23(9):781-792.
21. Physicians'Desk Reference 2009, 63rd ed. NewYork: Thomson Reuters; 2008.